Indirect comparisons between biologicals in active rheumatoid arthritis (RA) with inadequate response to anti-tumour necrosis factor (TNF), in ORs for American College of Rheumatology 50% improvement (ACR50) response rate at 6 months (week 24)
| ACR50 response rate | ||
|---|---|---|
| Indirect comparisons | OR (95% CI) | p Value |
| Tocilizumab24 Rituximab17 22 | 1.26 (0.42–3.78) | 0.67 |
| Tocilizumab24 Abatacept23 | 1.43 (0.39–5.21) | 0.58 |
| Abatacept23–rituximab17 22 | 0.88 (0.28 to 2.77) | 0.83 |
| Golimumab25–rituximab17 22 | 0.74 (0.24 to 2.30) | 0.60 |
| Golimumab25–abatacept23 | 0.84 (0.22 to 3.16) | 0.79 |
| Golimumab25–tocilizumab24 | 0.58 (0.16–2.11) | 0.41 |